The pharmaceutical actions of Rg3 on the inhibition of MMPs were: MMP2 in six cell lines (originated from lung, thyroid, nasopharynx, colorectum, and bone tumor), MMP9 in four cell lines (lung, thyroid, nasopharynx, and bone tumor), and MMP13 in the B16F10 melanoma cell line, respectively. Here, MMP9 is linked to bone neoplasm.